Funding aims to support development of a gonorrhea vaccine using NOMV technology.
- Carb-X invests in Adjane's vaccine project.
- NOMV platform shows promise for STI prevention.
- Funding aims to combat growing gonorrhea rates.
Carb-X, a global partnership aimed at stimulating the research and development of antibiotics, has awarded significant funding to Adjane. This investment focuses on advancing Adjane's innovative gonorrhea vaccine, which utilizes a novel platform called Non-typeable Outer Membrane Vesicles (NOMV). The introduction of this vaccine is seen as a crucial step in preventing the sexually transmitted infection caused by Neisseria gonorrhoeae.
Adjane's NOMV-derived vaccine aims to address the rising rates of gonorrhea globally, providing a potential solution to a pressing public health concern. With Carb-X's support, Adjane plans to further develop and optimize this vaccine to enhance its efficacy. This funding aligns with broader efforts to develop new vaccines for various STIs, reflecting an urgent need for improved prevention strategies.
The focus on gonorrhea vaccination is particularly relevant as antibiotic-resistant strains of the bacterium have become more prevalent. By employing the NOMV platform, Adjane is exploring a new approach that may offer robust immunity against gonorrhea. This initiative underscores the growing recognition of vaccines as a viable strategy in combating sexually transmitted infections.
